{"id":19481,"date":"2023-06-15T19:57:44","date_gmt":"2023-06-15T06:57:44","guid":{"rendered":"https:\/\/clladvocates.nz\/?p=19481"},"modified":"2023-06-15T19:57:44","modified_gmt":"2023-06-15T06:57:44","slug":"health-select-committees-report-into-the-therapeutic-products-bill","status":"publish","type":"post","link":"https:\/\/clladvocates.nz\/?p=19481","title":{"rendered":"Health Select Committee’s report into the Therapeutic Products Bill"},"content":{"rendered":"

 <\/p>\n

On Tuesday 14th of June, the Health Select Committee’s report into the Therapeutic Products Bill was released.\u00a0 It can be accessed here:\u00a0\u00a0Therapeutic Products Bill final report<\/a><\/p>\n

\u00a0This is what it means about the issues we had been highlighting:<\/div>\n
<\/div>\n
1.\u00a0 Rongo\u0101 M\u0101ori will be excluded from the Bill, except for when Rongo\u0101 M\u0101ori is being commercialised or exported.\u00a0 It would appear that this will happen via regulations, as opposed to Rongo\u0101 M\u0101ori being excluded in the Bill itself.<\/div>\n
<\/div>\n
2.\u00a0 Importation of prescribed medicines.\u00a0 This will remain as not being prohibited but with some potential guidelines that patients and clinicians\u00a0must follow.<\/div>\n
<\/div>\n
3.\u00a0 Advertisement of medicines.\u00a0 This has been further defined so that Givealittle pages and speaking publicly will not be within the definition of an advertisement.<\/div>\n
<\/div>\n
4.\u00a0 The responsibility of clinical trials will still be transferred from the Health Select Committee to Medsafe with no timeframe given by which decisions have to be made.\u00a0 This provision remains unchanged.<\/div>\n
<\/div>\n
5.\u00a0 There is no Section 29 equivalent in the new iteration of the Bill.\u00a0 It is very unclear how the Government intends to deal (or not) with patient access to unregistered medicines.<\/div>\n
\n

If you have had the chance to thoroughly review this report and have gained additional insights, please do to share your findings to: \u00a0clladvocates@outlook.co.nz or via our CLL Advocates Facebook group:\u00a0CLL Advocates Facebook group<\/a><\/p>\n

We have a significant amount of information to cover, and we are particularly concerned about the future of New Zealand’s clinical trial framework, especially regarding the absence of an equivalent to Section 29.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

  On Tuesday 14th of June, the Health Select Committee’s report into the Therapeutic Products Bill was released.\u00a0 It can […]<\/p>\n","protected":false},"author":2,"featured_media":19482,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[12,17],"tags":[67,68],"class_list":["post-19481","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-media","category-featured","tag-therapeutic-products-bill","tag-health-select-committee-blood-cancer-cll-leukaemia"],"jetpack_featured_media_url":"https:\/\/clladvocates.nz\/wp-content\/uploads\/2023\/06\/Parliament.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/19481","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19481"}],"version-history":[{"count":2,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/19481\/revisions"}],"predecessor-version":[{"id":19484,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/19481\/revisions\/19484"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/media\/19482"}],"wp:attachment":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19481"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19481"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19481"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}